Continuous spike-wave of slow sleep in a patient with KCNB1-related epilepsy responsive to highly purified cannabidiol: a case report and comparison with literature

References

• Abidin, R. R. (1995). Parenting stress index, third edition: Professional manual. Psychological Assessment Resources, Inc.
   Google Scholar
• Achenbach, T. M., & Rescorla, L. A. (2004). The Achenbach System of Empirically Based Assessment (ASEBA) for ages 1.5 to 18 years. In M. Maruish (Ed.), The use of psychological testing for treatment planning and outcomes assessment: Instruments for children and adolescents (3rd ed., Vol. 2, pp. 179–213). Lawrence Erlbaum Associates Publishers.
   Google Scholar
• Anderson, L. L., Absalom, N. L., Abelev, S. V., Low, I. K., Doohan, P. T., Martin, L. J., Chebib, M., McGregor, I. S., & Arnold, J. C. (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 60(11), 2224–2234. https://doi.org/10.1111/epi.16355
   PubMed Web of Science ®Google Scholar
• Bar, C., Kuchenbuch, M., Barcia, G., Schneider, A., Jennesson, M., Le Guyader, G., Lesca, G., Mignot, C., Montomoli, M., Parrini, E., Isnard, H., Rolland, A., Keren, B., Afenjar, A., Dorison, N., Sadleir, L. G., Breuillard, D., Levy, R., Rio, M. & Nabbout, R. (2020). Developmental and epilepsy spectrum of KCNB1 encephalopathy with long-term outcome. Epilepsia, 61(11), 2461–2473. https://doi.org/10.1111/epi.16679
   PubMed Web of Science ®Google Scholar
• Buzatu, M., Bulteau, C., Altuzarra, C., Dulac, O., & Van Bogaert, P. (2009). Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia, 50(Suppl 7), 68–72. https://doi.org/10.1111/j.1528-1167.2009.02224.x
   PubMedGoogle Scholar
• Caraballo, R., Reyes, G., Demirdjian, G., Huaman, M., & Gutierrez, R. (2022). Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy. Seizure: European Journal of Epilepsy, 95, 56–63. https://doi.org/10.1016/j.seizure.2022.01.001
   PubMed Web of Science ®Google Scholar
• Downs, J., Jacoby, P., Leonard, H., Epstein, A., Murphy, N., Davis, E., Reddihough, D., Whitehouse, A., & Williams, K. (2019). Psychometric properties of the quality of life inventory-disability (QI-Disability) measure. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 28(3), 783–794. https://doi.org/10.1007/s11136-018-2057-3
   PubMed Web of Science ®Google Scholar
• Ferrera, G., Ricci, E., Vignoli, A., Savini, M. N., Viganò, I., Chiesa, V., Caputo, D., Zambrelli, E., La Briola, F., Turner, K., & Canevini, M. P. (2023). Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center. Epilepsy & Behavior: E&B, 147, 109409. https://doi.org/10.1016/j.yebeh.2023.109409
   PubMed Web of Science ®Google Scholar
• Frigerio, A., Cattaneo, C., Cataldo, M. G., Schiatti, A., Molteni, M., & Battaglia, M. (2004). Behavioral and emotional problems among Italian children and adolescents aged 4 to 18 years as reported by parents and teachers. European Journal of Psychological Assessment, 20(2), 124–133. https://doi.org/10.1027/1015-5759.20.2.124
   Web of Science ®Google Scholar
• Ghovanloo, M.-R., Shuart, N. G., Mezeyova, J., Dean, R. A., Ruben, P. C., & Goodchild, S. J. (2018). Inhibitory effects of cannabidiol on voltage-dependent sodium currents. The Journal of Biological Chemistry, 293(43), 16546–16558. https://doi.org/10.1074/jbc.RA118.004929
   PubMed Web of Science ®Google Scholar
• Golub, V., & Reddy, D. S. (2021). Cannabidiol therapy for refractory epilepsy and seizure disorders. Advances in Experimental Medicine and Biology, 1264, 93–110. https://doi.org/10.1007/978-3-030-57369-0_7
   PubMed Web of Science ®Google Scholar
• Grayson, L., Ampah, S., Hernando, K., Kankirawatana, P., Gaston, T., Cutter, G., Szaflarski, J. P., & Martina Bebin, E. (2021). Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy. Epilepsy & Behavior: E&B, 122, 108190. https://doi.org/10.1016/j.yebeh.2021.108190
   PubMed Web of Science ®Google Scholar
• Guarino, A., DiBlasio, P., D’alessio, M., Camisasca, E., & Serantoni, M. (2008). Parenting stress index short form: Adattamento italiano. Giunti, Organizzazioni Speciali.
   Google Scholar
• Marini, C., Romoli, M., Parrini, E., Costa, C., Mei, D., Mari, F., Parmeggiani, L., Procopio, E., Metitieri, T., Cellini, E., Virdò, S., De Vita, D., Gentile, M., Prontera, P., Calabresi, P., & Guerrini, R. (2017). Clinical features and outcome of 6 new patients carrying de novo KCNB1 gene mutations. Neurology Genetics, 3(6), e206. https://doi.org/10.1212/NXG.0000000000000206
   PubMed Web of Science ®Google Scholar
• Nabbout, R., Arzimanoglou, A., Auvin, S., Berquin, P., Desurkar, A., Fuller, D., Nortvedt, C., Pulitano, P., Rosati, A., Soto, V., Villanueva, V., & Cross, J. H. (2023). Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with lennox-gastaut syndrome or Dravet syndrome. Seizure: European Journal of Epilepsy, 110, 78–85. https://doi.org/10.1016/j.seizure.2023.05.003
   PubMed Web of Science ®Google Scholar
• Oz, M., Yang, K.-H., Dinc, M., & Shippenberg, T. S. (2007). The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed xenopus oocytes. The Journal of Pharmacology and Experimental Therapeutics, 323(2), 547–554. https://doi.org/10.1124/jpet.107.125336
   PubMed Web of Science ®Google Scholar
• Palacio, S., Chevaleyre, V., Brann, D. H., Murray, K. D., Piskorowski, R. A., & Trimmer, J. S. (2017). Heterogeneity in Kv2 channel expression shapes action potential characteristics and firing patterns in CA1 versus CA2 hippocampal pyramidal neurons. ENeuro, 4(4), ENEURO.0267–17.2017. https://doi.org/10.1523/ENEURO.0267-17.2017
   PubMed Web of Science ®Google Scholar
• Szaflarski, J. P., Hernando, K., Bebin, E. M., Gaston, T. E., Grayson, L. E., Ampah, S. B., & Moreadith, R. (2019). Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy & Behavior: E&B, 95, 131–136. https://doi.org/10.1016/j.yebeh.2019.03.042
   PubMed Web of Science ®Google Scholar
• van den Munckhof, B., de Vries, E. E., Braun, K. P. J., Boss, H. M., Willemsen, M. A., van Royen-Kerkhof, A., de Jager, W., & Jansen, F. E. (2016). Serum inflammatory mediators correlate with disease activity in electrical status epilepticus in sleep (ESES) syndrome. Epilepsia, 57(2), e45–50. https://doi.org/10.1111/epi.13274
   PubMed Web of Science ®Google Scholar
• Watkins, A. R. (2019). Cannabinoid interactions with ion channels and receptors. Channels (Austin, Tex), 13(1), 162–167. https://doi.org/10.1080/19336950.2019.1615824
   PubMed Web of Science ®Google Scholar
• Zhang, H.-X. B., Heckman, L., Niday, Z., Jo, S., Fujita, A., Shim, J., Pandey, R., Al Jandal, H., Jayakar, S., Barrett, L. B., Smith, J., Woolf, C. J., & Bean, B. P. (2022). Cannabidiol activates neuronal Kv7 channels. ELife, 11. https://doi.org/10.7554/eLife.73246
   Web of Science ®Google Scholar